Main Article Content

Cardiac involvement in cancer patients under chemotherapy and diagnosed with COVID-19: case report and literature review


Hanane Mechal
Rime Benmalek
Hamza Choukrallah
Anas Maaroufi
Rachida Habbal
El Ghali Mohamed Benouna
Anass Mounir
Khalid Allali
Rachid Cherkab
Lhoucine Barrou
Chafik El Kettani

Abstract

Many cases of severe cardiac complications due to coronavirus disease 2019 (COVID-19) were reported. Cancer and chemotherapy appear to be risk and prognostic factors for COVID-19. A 49-year-old female, with a history of breast cancer treated by tumorectomy and anthracycline-based chemotherapy was admitted with acute respiratory distress syndrome (ARDS) confirmed as COVID-19. She also had elevated troponin I level (up to 43 g/L), and diffuse myocardial hypokinesia along with severe left ventricle dysfunction on echocardiography. Initial treatment included hydroxychloroquine, azithromycin, corticosteroids and mechanical ventilation. The evolution was marked by QT interval prolongation (QTc=523 ms) and occurrence of cardiogenic shock. The patient died of hemodynamic instability reluctant to resuscitation measures at the 2nd day of hospitalization. COVID-19 patients may develop severe cardiac complications such as myocarditis and heart failure. Receiving chemotherapy especially anthracyclines may be a precipitating and prognostic factor of cardiac manifestations in COVID-19 cancer patients.


Journal Identifiers


eISSN: 1937-8688